Skip to main content

Equillium, Inc. (EQ)

NASDAQ: EQ · IEX Real-Time Price · USD
6.21 0.34 (5.71%)
Oct 21, 2021 12:57 PM EDT - Market open
Market Cap172.48M
Revenue (ttm)n/a
Net Income (ttm)-33.66M
Shares Out29.08M
EPS (ttm)-1.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume58,014
Open5.84
Previous Close5.87
Day's Range5.60 - 6.38
52-Week Range3.47 - 11.33
Beta1.50
AnalystsStrong Buy
Price Target14.00 (+125.6%)
Est. Earnings DateNov 10, 2021

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceu...

IndustryBiotechnology
IPO DateOct 11, 2018
CEOBruce Steel
Employees31
Stock ExchangeNASDAQ
Ticker SymbolEQ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Equillium stock is "Strong Buy." The 12-month stock price forecast is 14.00, which is an increase of 125.62% from the latest price.

Price Target
$14.00
(125.62% upside)
Analyst Consensus: Strong Buy

News

Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrolo...

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

3 days ago - Business Wire

Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

3 weeks ago - Business Wire

Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

4 weeks ago - Business Wire

Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unme...

1 month ago - Business Wire

Equillium's Itolizumab Reduces Urine Protein In Lupus Patients

Equillium Inc (NASDAQ: EQ) announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN). The new data sho...

2 months ago - Benzinga

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Ne...

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #lupus--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with hi...

2 months ago - Business Wire

Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medica...

2 months ago - Business Wire

Equillium to Present at the BTIG Virtual Biotechnology Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #asthma--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, annou...

2 months ago - Business Wire

Equillium's Single Phase 3 Study In aGVHD To Support US Filing Of Itolizumab

Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line treatment of acute graft-versus-host disea...

3 months ago - Benzinga

Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Vers...

Single pivotal Phase 3 study in acute graft-versus-host disease to support filing of biologics license application

3 months ago - GlobeNewsWire

4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other symbols:CKPTFLXNRSLS
4 months ago - 24/7 Wall Street

Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients

Equillium Inc (NASDAQ: EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD). The results were presented at t...

4 months ago - Benzinga

Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host...

Itolizumab continues to demonstrate favorable safety and efficacy profile

4 months ago - GlobeNewsWire

Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International So...

Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases Whole blood and proteomic stabilized blood assay used to elicit clinical pha...

4 months ago - GlobeNewsWire

Equillium to Present at the JMP Securities Life Sciences Conference

LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, anno...

4 months ago - GlobeNewsWire

Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-...

LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today...

4 months ago - GlobeNewsWire

Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Dis...

Presentation and conference call will include topline data from all cohorts

4 months ago - GlobeNewsWire

Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update

Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus

5 months ago - GlobeNewsWire

Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Dis...

LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today...

5 months ago - GlobeNewsWire

Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association...

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients Presentati...

5 months ago - GlobeNewsWire

Equillium's Itolizumab Shows Encouraging Safety, Tolerability Profile In Systemic Lupus Erythematosus Study

Equillium Inc (NASDAQ: EQ) has reported topline data from the Type A group of the Phase 1b EQUALISE study evaluating itolizumab in patients with systemic lupus erythematosus (SLE). Data from the study s...

6 months ago - Benzinga

Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients

Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus

6 months ago - GlobeNewsWire

Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th ...

EQUATE acute graft-versus host disease (aGVHD) study observed  rapid response and durability through day 85

7 months ago - GlobeNewsWire

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Di...

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial  reduction in baseline corticosteroid use

8 months ago - GlobeNewsWire